When the US Biologics Price Competition and Innovation Act set out the country’s biosimilars framework in 2009, it contained within it a significant provision that would set the US apart from other markets in its treatment of biosimilarity, in the form of an additional designation for “interchangeable” biosimilars.
Interchangeability is defined by the BPCIA as a separate standard to biosimilarity, and requires a product to not only be...